Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$139.02 USD

139.02
2,616,684

+10.04 (7.78%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y

Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.

    Pacific Biosciences (PACB) Loss In Line With Estimates in Q2

    Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.

      DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View

      Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.

        Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid

        Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.

          The Zacks Analyst Blog Highlights: Microsoft, Micron, Amazon.com, Illumina and Activision

          The Zacks Analyst Blog Highlights: Microsoft, Micron, Amazon.com, Illumina and Activision

            CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance

            CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.

              Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance

              Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.

                DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

                Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.

                  Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3

                  Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.

                    Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall

                    Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.

                      AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues

                      AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.

                        Tirthankar Chakraborty headshot

                        Tariff Woes Haunt Wall Street: Take Refuge in These 5 Stocks

                        Companies involved in artificial intelligence, e-commerce, biotechnology and gaming businesses are immune to trade conflicts. They are part of an evolving trend that provides stability during tough times and their quest for the next big thing fuels growth.

                          Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day

                          Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day

                            Madeleine Johnson headshot

                            Bull of the Day: Illumina (ILMN)

                            Invest in the medical space with this DNA sequencing-focused company.

                              Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates

                              Lower peritoneal dialysis sales in Q2 hurt Fresenius Medical (FMS); solid geographical performance encourages.

                                Ecolab (ECL) Q2 Earnings In Line, Revenues Beat Estimates

                                Solid performance in the Global Industrial and Global Institutional segments boost Ecolab's (ECL) top line in Q2.

                                  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

                                  Is (ILMN) Outperforming Other Medical Stocks This Year?

                                    Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance

                                    Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.

                                      athenahealth (ATHN) Beats on Q2 Earnings, Raises '19 View

                                      An upbeat 2018 guidance instills investor's optimism for athenahealth (ATHN). However, lackluster performance in the Implementation and other segment is a persistent headwind.

                                        Sprint (S) Gears Up for Q1 Earnings: What's in the Cards?

                                        Sprint (S) is likely to report lower revenues in first-quarter fiscal 2018 on a year-over-year basis due to weak demand patterns in the industry.

                                          What's in the Cards for Arena (ARNA) This Earnings Season?

                                          With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.

                                            Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates

                                            Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.

                                              Abiomed (ABMD) Lags Q1 Earnings Estimates, Raises '19 View

                                              Abiomed's (ABMD) flagship Impella line continues to drive growth in Q1. A strong guidance instills investors' optimism.

                                                Why Earnings Season Could Be Great for Illumina (ILMN)

                                                Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                                  Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

                                                  Sector ETF report for ARKG